Youssef, Mina
De Sanctis, Juan B.
Shah, Juhi
Dumut, Daciana Catalina
Hajduch, Marian
Petrof, Basil J.
Radzioch, Danuta http://orcid.org/0000-0002-1601-2757
Funding for this research was provided by:
Cystic Fibrosis Canada (494470)
ENOCH Molecular (CZ.02.1.01/0.0/0.0/16_019/0000868)
Canadian Institute of Health Research (2433990)
Article History
Received: 17 December 2019
Accepted: 2 April 2020
First Online: 18 April 2020
Compliance with Ethical Standards
:
: The corresponding author, Dr. Radzioch, PrincipalĀ InvestigatorĀ at the Research Institute of the McGill University Health Centre and Professor at McGill University, is a minor shareholder of Laurent Pharmaceuticals Inc. which generously (free of charge) provided the clinical capsules used for treatment of <i>Cftr</i> KO mice and their littermate controls. The studies presented have not been otherwise financially supported by Laurent Pharmaceuticals Inc. and neither the first author nor any other co-author have any conflicts of interest to declare associated with this publication.
: All experimental procedures were conducted in accordance with and approval of the Animal Care Committee of the McGill University Health Centre, Montreal, Quebec, Canada.